Dr. Peter Kabos, MD
Medical Oncology (Medical Oncology Physician)
12605 E 16th Ave
Aurora, CO 80045
Who else practices at this address →
Adams County includes primary care (2% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 96
Licensed in Colorado since 2007, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CO license DR.0046170 (first issued 2007; active) -
Hematology & Oncology Physician
CO license 46170 (first issued 2007; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Colorado Hospital Authority Aurora, CO
- Uchealth Highlands Ranch Hospital Highlands Ranch, CO
Medical groups
- University Physicians Incorporated (3,215 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 96
- Services billed
- 283
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 150 | 39 |
| Established patient office or other outpatient visit, 30-39 minutes | 105 | 68 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
| Established patient office or other outpatient visit, 20-29 minutes | 14 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Aurora, CO | 95 |
| Anastrozole Other prescribers in Aurora, CO | 63 |
| Gabapentin Other prescribers in Aurora, CO | 18 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Aurora, CO | 17 |
| Exemestane | 15 |
| Kisqali (ribociclib succinate) | 15 |
| Eliquis (apixaban) Other prescribers in Aurora, CO | 12 |
| Oxycodone Hcl Other prescribers in Aurora, CO | 12 |
| Prochlorperazine Maleate Other prescribers in Aurora, CO | 12 |
| Xarelto (rivaroxaban) Other prescribers in Aurora, CO | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 3 payments worth $4,138 in total to this clinician.
| AbbVie Inc. | $2,538 |
|---|---|
| Lilly USA, LLC | $1,600 |
| Consulting Fee | $4,138 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Jan 2, 2025 | Consulting Fee | $1,813 |
| Lilly USA, LLC Jun 24, 2025 | Consulting Fee | $1,600 |
| AbbVie Inc. Jan 21, 2025 | Consulting Fee | $725 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 4 companies. The companies reported $154,878 in research payments for these studies, mostly to the institutions running them.
- A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals Inc. - A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Positive, HER2 Negative Advanced Breast Cancer
AstraZeneca Pharmaceuticals LP - A randomized phase ii trial of circulating tumor dnaguided second line adjuvant therapy for high residual risk estrogen receptor positive HER2 negative breast cancer DAREWI251141
Pfizer Inc. - The COMPASSHER2 trials comprehensive use of pathologic response assessment to optimize therapy in HER2POSITIVE breast cancer COMPASSHER2 residual disease rd a doubleblinded phase iii randomized trial of TDM1 compared …
Pfizer Inc. - Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers
Jazz Pharmaceuticals Inc. - A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.